These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24876881)

  • 1. In Silico Investigation of Potential PARP-1 Inhibitors from Traditional Chinese Medicine.
    Chen KC; Sun MF; Chen CY
    Evid Based Complement Alternat Med; 2014; 2014():917605. PubMed ID: 24876881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico investigation of potential mTOR inhibitors from traditional Chinese medicine for treatment of Leigh syndrome.
    Chen KC; Lee WY; Chen HY; Chen CY
    Biomed Res Int; 2014; 2014():139492. PubMed ID: 25045657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair.
    Dantzer F; Amé JC; Schreiber V; Nakamura J; Ménissier-de Murcia J; de Murcia G
    Methods Enzymol; 2006; 409():493-510. PubMed ID: 16793420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural inhibitors of poly(ADP-ribose) polymerase-1.
    Banasik M; Stedeford T; Strosznajder RP
    Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
    van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.
    Tou WI; Chen CY
    PLoS One; 2012; 7(3):e33728. PubMed ID: 22470466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.
    Harrision D; Gravells P; Thompson R; Bryant HE
    Front Mol Biosci; 2020; 7():191. PubMed ID: 33005627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The
    Taipakova S; Kuanbay A; Saint-Pierre C; Gasparutto D; Baiken Y; Groisman R; Ishchenko AA; Saparbaev M; Bissenbaev AK
    Front Cell Dev Biol; 2020; 8():606596. PubMed ID: 33324653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of simulated microgravity conditions on poly(ADP-ribose) polymerase activity in primary cultures of adult rat hepatocytes.
    Cesarone CF; Pippia P; Demori I; Scarabelli L; Fugassa E
    J Gravit Physiol; 2001 Jul; 8(1):P127-8. PubMed ID: 12650200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
    Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
    BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
    Shah AP; Patel CN; Sureja DK; Sanghavi KP
    Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L; Szabó C
    Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts.
    Parsons JL; Dianova II; Allinson SL; Dianov GL
    FEBS J; 2005 Apr; 272(8):2012-21. PubMed ID: 15819892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis.
    Langelier MF; Pascal JM
    Curr Opin Struct Biol; 2013 Feb; 23(1):134-43. PubMed ID: 23333033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
    Komjáti K; Besson VC; Szabó C
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative site-specific ADP-ribosylation profiling of DNA-dependent PARPs.
    Gagné JP; Ethier C; Defoy D; Bourassa S; Langelier MF; Riccio AA; Pascal JM; Moon KM; Foster LJ; Ning Z; Figeys D; Droit A; Poirier GG
    DNA Repair (Amst); 2015 Jun; 30():68-79. PubMed ID: 25800440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase.
    Kim IK; Stegeman RA; Brosey CA; Ellenberger T
    J Biol Chem; 2015 Feb; 290(6):3775-83. PubMed ID: 25477519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational investigation of FDA approved drugs as selective PARP-1 inhibitors by targeting BRCT domain for cancer therapy.
    Kumar C; Lakshmi PTV; Arunachalam A
    J Mol Graph Model; 2021 Nov; 108():107919. PubMed ID: 34304979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.